How to Read Your Labs on CJC-1295 and Ipamorelin (2026)

CJC-1295 and ipamorelin is the most-searched GH peptide stack of 2026, and the most-confused. Every clinic blog tells you to "monitor your bloodwork," then stops. Nobody tells you which markers, when to draw, what numbers signal trouble, or why your IGF-1 sometimes refuses to move even when the peptide is real and the dose is right. This guide fills that gap with specific reference ranges, draw timing, and head-to-head comparisons to MK-677 and tesamorelin.

How CJC-1295 and ipamorelin actually work

Two peptides, two receptors, one amplified GH pulse. CJC-1295 no-DAC is a stabilised GHRH analog. It primes the somatotrophs in your pituitary, lowering the threshold for GH release and upregulating the receptor that ipamorelin binds. Ipamorelin is a GHRP, a ghrelin receptor agonist that triggers the actual release. Used alone, each produces a modest GH pulse. Used together, they produce a synergistic pulse that exceeds the sum of the parts (Bowers et al., 1990).

GHRH plus GHRP synergy

The mechanism is well established. GHRH (CJC-1295) acts on the GHRH receptor through cAMP and PKA. GHRP (ipamorelin) acts on the GHS-R1a ghrelin receptor through IP3 and intracellular calcium. Independent pathways, additive output. Veldhuis and Bowers (2009) demonstrated that combined GHRH plus GHRP-2 in healthy men produces GH peaks substantially higher than either alone, and that baseline IGF-1 and IGFBP-3 are positive predictors of the synergy magnitude. Visceral fat is a negative predictor, which is one reason older or fatter users see blunted responses.

The two CJC-1295 variants matter more than most users realise. No-DAC has a half-life of roughly 30 minutes and produces a single GH pulse per injection. The DAC variant covalently binds albumin and has a half-life of 5.8 to 8.1 days (Teichman et al., 2006). DAC produces sustained, elevated GH for days, which is more like exogenous GH than a physiological pulse and tends to downregulate GHS-R sensitivity over time. No-DAC is the bodybuilder default for that reason. When you read about "50 to 200% IGF-1 elevations" from CJC-1295 studies, those numbers come from the DAC variant in a clinical trial setting, not from the pre-bed no-DAC protocol most people actually run.

Why pulsatile matters for your bloodwork

This is the core distinction from MK-677. CJC-1295 plus ipamorelin produces one or two discrete GH pulses per day, peaking around 30 to 60 minutes post-injection and returning to baseline within 2 to 3 hours (Tiulpakov et al., 1995). Between pulses, your somatostatin feedback loop works normally, free fatty acid flux returns to baseline, and your liver and muscle regain insulin sensitivity. This is why fasting glucose and HbA1c barely move on CJC/Ipa, while MK-677 reliably nudges both upward over time.

The bloodwork implication: most of the action you see on labs is the cumulative IGF-1 response, not the acute GH pulse. IGF-1 is hepatically produced, lags GH by hours to days, and integrates the signal over time. Drawing IGF-1 within 3 hours of an injection captures nothing useful. Draw fasted, in the morning, at least 12 to 16 hours after the last shot.

The 8-marker CJC/ipamorelin bloodwork panel

A clinic that tells you to "monitor your bloodwork" without specifying markers is selling you peptides, not safety. Here is the actual panel.

IGF-1: the efficacy marker

IGF-1 is the primary efficacy readout. It confirms your peptide is real, your dose is sufficient, and your somatotrophs are responding. Healthy adult male reference range varies by lab and assay, but 150 to 350 ng/mL captures most 20 to 40 year olds (Sabbah et al., 2021).

What to expect at standard dosing (100 mcg CJC-1295 no-DAC plus 200 to 300 mcg ipamorelin, once pre-bed): a 15 to 40% rise over baseline at 6 to 8 weeks. If your baseline is 180 ng/mL, expect 210 to 250 ng/mL at steady state. More aggressive protocols (twice or three times daily dosing) push higher but at progressively diminishing return. Sigalos et al. (2017) showed that hypogonadal men on a GHRP-6, GHRP-2, and sermorelin protocol three times daily lifted IGF-1 from 159.5 to 239.0 ng/mL over 134 days, a 50% rise.

IGFBP-3 and the IGF-1/IGFBP-3 ratio

IGFBP-3 is the paired safety marker most users skip. It binds 80 to 90% of circulating IGF-1 and determines how much free, biologically active IGF-1 reaches tissues. When you stimulate GH, both IGF-1 and IGFBP-3 should co-elevate proportionally. Endocrinologists use the molar IGF-1/IGFBP-3 ratio rather than absolute IGF-1 to judge whether GH dosing is safe in long-term replacement therapy (Siklar et al., 2009).

If IGF-1 climbs but IGFBP-3 lags, free IGF-1 rises disproportionately. That is the marker for trouble: more biologically active IGF-1 hitting tissues, more growth signalling, more long-term cancer and acromegaly risk. Always order both together. This is how endocrinologists monitor real GH replacement and it is the standard you should match.

Fasting glucose, HbA1c, fasting insulin, HOMA-IR

GH is counter-regulatory to insulin. Even pulsatile GH transiently raises blood glucose during the pulse window. The question for bloodwork is whether that translates into sustained insulin resistance, and the answer for CJC/Ipa is mostly no.

The best proxy is tesamorelin, the only GHRH analog with Phase III data. Stanley et al. (2011) measured tesamorelin 2 mg/day for 2 weeks in healthy men: IGF-1 rose 181 mcg/L, fasting glucose was unchanged (p = 0.93), and insulin-stimulated glucose uptake was unchanged (p = 0.61). Pulsatile GHRH activation simply does not produce the sustained insulin resistance that continuous GH does.

Compare that to MK-677. Nass et al. (2008) ran a 2-year RCT of MK-677 25 mg/day in healthy older adults: fasting glucose rose 5 mg/dL (p = 0.015), HbA1c trended upward by roughly 0.2 percentage points, and insulin sensitivity decreased. Modest in healthy older adults, more meaningful for a bodybuilder already running aromatising compounds and eating in a surplus.

Track fasting glucose, HbA1c, and fasting insulin. Calculate HOMA-IR: (glucose mmol/L × insulin mIU/L) / 22.5. For a young lean athlete, HOMA-IR below 1.0 is optimal. Above 2.0 to 2.5 is your dose-reduction flag, well before fasting glucose ever crosses the 100 mg/dL prediabetes threshold.

Cortisol and prolactin: the selectivity check

Ipamorelin's cortisol neutrality is what distinguishes it from every other GHRP on the market. Raun et al. (1998) tested ipamorelin head-to-head against GHRP-6, GHRP-2, and hexarelin. At doses more than 200 times the GH-effective dose, ipamorelin produced no ACTH or cortisol elevation different from baseline. FSH, LH, prolactin, and TSH were also unaffected. The other GHRPs all raised cortisol and ACTH at therapeutic doses (Arvat et al., 1997).

Why this matters in your bloodwork: cortisol and prolactin should not move on ipamorelin. If they do, look elsewhere (training stress, sleep debt, dopamine antagonists, nandrolone use). Baseline these markers before starting so you can attribute future changes correctly. Hexarelin and the older GHRPs would push cortisol up, sometimes substantially. That cortisol bump compounds the catabolic pressure of a cut, disrupts sleep architecture, and undermines the whole point of running a GH peptide. Ipamorelin's selectivity is the entire reason it has displaced hexarelin and GHRP-6 in performance use.

HDL, LDL, triglycerides

GH peptides do not behave like anabolic steroids on lipids. Where AAS tank HDL by 40 to 70% and push LDL up, GH-axis activation tends to preserve or improve the lipid profile. The clearest data comes from tesamorelin Phase III (Falutz et al., 2010): triglycerides dropped 37 mg/dL at 26 weeks and 48 mg/dL at 52 weeks, total cholesterol dropped 8 mg/dL, and the cholesterol/HDL ratio improved 7.2%.

The mechanism: GH and IGF-1 upregulate hepatic LDL receptor expression and increase LDL fractional catabolic rate. Christ et al. (2004) showed this directly in GH-deficient adults on replacement therapy, with LDL apoB concentrations falling through faster clearance rather than reduced production.

For CJC-1295/Ipa specifically, no controlled human trial has measured lipid endpoints, but the GHRH-class mechanism strongly suggests neutral-to-favourable changes. If you are stacking with oral AAS, your lipid panel will still look bad, just less bad than steroids alone.

TSH and free T4

Rare but documented. GH activation upregulates type 1 deiodinase, increasing T4 to T3 conversion, which can transiently lower free T4 and unmask subclinical hypothyroidism. Smyczynska et al. (2010) found that 17 of 75 children (about 23%) starting rhGH therapy developed transient subclinical hypothyroidism at 3 to 6 months, with free T4 normalising over the following year. In adults on rhGH (Losa et al., 2008), the incidence is much lower: 6.7 events per 100 patient-years.

For CJC/Ipa users, the practical guidance is simple: baseline TSH and free T4, recheck at 12 weeks. If free T4 drifts toward the low end of normal and you develop symptoms (fatigue, cold intolerance), see an endocrinologist before assuming it is something else.

Why your IGF-1 did not move

This is the question no other competitor article answers. Forums are full of frustrated users seeing flat IGF-1 after 8 weeks of a stack they paid real money for. Here is the decision tree.

Step 1: was the draw timed correctly?

If you drew within 3 hours of your last injection, you may have caught the GH pulse but missed the IGF-1 response. IGF-1 is hepatically produced and lags GH by hours to days. Fasting morning draw, 12 to 16 hours post-injection, is the right protocol. This alone explains a large share of "flat" results.

Step 2: is the dose and frequency sufficient?

Single pre-bed dosing produces one physiological GH pulse per 24 hours. That is enough to nudge IGF-1 modestly in most users but will not produce the 50% rises seen in three-times-daily clinical protocols. If your baseline IGF-1 was 200 ng/mL and your follow-up is 220 ng/mL, that is a 10% rise. Within assay noise, sure, but also consistent with a real effect at low dosing frequency. Consider twice-daily or three-times-daily dosing before concluding the protocol failed.

Step 3: is the product real?

GHRH and GHRP peptides are heat-sensitive, susceptible to bacterial contamination, and routinely degraded by sloppy lyophilisation, repeated freeze-thaw cycles, or improper reconstitution. Underground lab quality varies wildly. If you are running an unverified source and your IGF-1 will not budge after correct timing and adequate dosing, product purity is the most likely culprit. Switch sources, redraw at 6 weeks.

Step 4: are you a low responder?

Visceral fat is a negative predictor of GHRH/GHRP synergy (Veldhuis and Bowers, 2009). Low baseline testosterone blunts the GH axis. GHS-R loss-of-function variants exist (rare, no routine clinical test). And pituitary somatotroph reserve declines with age. If you are 45 with a softer body composition and a baseline testosterone of 350 ng/dL, expect a smaller response than a lean 25-year-old with testosterone of 900.

Step 5: are you already at the ceiling?

If your baseline IGF-1 is already 300 ng/mL because you are young, lean, well-fed, and well-rested, there is not much headroom. The peptide may be working as designed but producing a modest absolute increase that looks flat in percentage terms.

When to draw each marker

Baseline matters more than any follow-up draw. Without it, you cannot tell whether the peptide is doing anything or whether numbers were already where they are.

All draws should be fasted, morning, at least 12 to 16 hours after the last injection. Cortisol is time-sensitive: draw between 7 and 9 AM. If you are also on TRT, draw testosterone at the same trough timing you normally use so you can compare against historical data.

CJC/Ipa vs MK-677 head-to-head

Different mechanisms, different bloodwork, different decision criteria. The choice is not "which is better" but "which problem are you solving."

The MK-677 IGF-1 ceiling is higher on paper because continuous 24-hour GH exposure produces more hepatic IGF-1 output than pulsatile. The cost is the metabolic profile: glucose creep, HbA1c drift, cortisol elevation, and appetite stimulation that drives a caloric surplus even when you do not want one. For a bodybuilder in a bulk who wants oral convenience and does not care about glucose, MK-677 makes sense. For anyone in a cut, anyone metabolically sensitive, or anyone who values clean cortisol and prolactin numbers, CJC/Ipa is the cleaner choice. Our deeper coverage of MK-677's glucose problem and the MK-677 monitoring protocol lays out the metabolic case in detail.

CJC/Ipa vs tesamorelin: which numbers differ

Tesamorelin is the GHRH analog you have probably never heard of, and the only one with FDA approval (HIV lipodystrophy, 2010). It is also the GH peptide with the strongest published evidence base for body composition outcomes in humans.

The Phase III data (Falutz et al., 2010, 806 patients, 26-week intervention plus extension) is striking: visceral fat dropped 15.4% (treatment effect), triglycerides dropped 37 mg/dL, total cholesterol dropped 8 mg/dL, cholesterol/HDL ratio improved 7.2%, IGF-1 rose 108 ng/mL absolute. No clinically meaningful glucose changes. This is what robust GHRH-class evidence looks like, and CJC-1295's mechanism is similar enough that tesamorelin data is the cleanest available proxy for what CJC/Ipa probably does.

When to consider tesamorelin over CJC/Ipa:

• You are over 40 with visible visceral adiposity. Tesamorelin selectively reduces VAT without subcutaneous fat loss.
• Your baseline triglycerides are elevated. The triglyceride response is unique among GH secretagogues.
• You value evidence over cost. Tesamorelin is FDA-approved and trial-validated. CJC/Ipa is not.

When CJC/Ipa wins:

• Cost. Tesamorelin is considerably more expensive per month.
• Frequency. CJC/Ipa as a single pre-bed pulse is more convenient than tesamorelin's daily 2 mg dose.
• You want the GHRP component for ghrelin-axis effects (sleep depth, appetite, recovery), not just the GHRH side.

Stacking with a GLP-1: retatrutide, tirzepatide, semaglutide

The other thing happening in 2026 is that everyone running CJC/Ipa is also running a GLP-1. The logic is rational: GLP-1 (or GLP-1/GIP, or triple agonist) creates the caloric deficit that drives fat loss; GH peptide provides anabolic signal to bias the body away from muscle during that deficit.

The lean mass numbers from the GLP-1 trials are the reason the stack exists. SURMOUNT-1 (tirzepatide 15 mg, 72 weeks) saw mean total body weight loss of 20.9%, with roughly 25% of that loss coming from lean tissue. For a 100 kg user losing 21 kg, that is ~5 kg of lean mass. Not trivial. The retatrutide TRIUMPH-1 analysis breaks down the muscle loss math in detail.

CJC/Ipa is the logical counter, though no controlled trial has tested the combination directly. By mechanism, the case is solid: pulsatile GHRH stimulation preserves insulin sensitivity even under caloric deficit (tesamorelin data, Stanley et al., 2011), and IGF-1 elevation protects against the lean mass loss inherent to aggressive deficits.

What changes on your bloodwork when stacking:

• HbA1c trajectory is dominated by the GLP-1. Expect downward movement regardless of CJC/Ipa contribution. Track it but do not panic if it falls below 5.0%.
• IGF-1 may show smaller absolute elevation. Caloric restriction modestly suppresses IGF-1. CJC/Ipa is fighting against that suppression, so the peptide may be normalising IGF-1 rather than pushing it supraphysiological.
• Triglycerides improve on both compounds. Expect substantial drops by week 8 to 12.
• Cortisol may drift up modestly during aggressive caloric deficits. Ipamorelin's cortisol neutrality protects you here. Older GHRPs would compound the cortisol pressure.
• HOMA-IR usually improves. GLP-1 net-improves insulin sensitivity, CJC/Ipa is neutral. The combined effect is favourable.

Retatrutide adds glucagon receptor agonism, which is counter-regulatory to insulin and raises hepatic glucose output. If you are running retatrutide plus CJC/Ipa, check fasting glucose more often than you would on tirzepatide or semaglutide. Glucagon plus GH stacking has not been studied in humans and is the most pharmacologically aggressive metabolic combination you can run.

Action thresholds: when to pause, lower, or switch

Numbers without action thresholds are noise. Here are the thresholds that should drive a real change.

Pause and reassess immediately if:

• IGF-1 above 500 ng/mL with low IGFBP-3 (ratio out of range)
• Fasting glucose persistently above 110 mg/dL (6.1 mmol/L)
• HbA1c above 5.7% on follow-up after starting (and you were below it at baseline)
• Persistent cortisol elevation (suggests product is not real ipamorelin)
• Persistent prolactin elevation (same)

Lower dose or frequency if:

• IGF-1 between 400 and 500 ng/mL
• HOMA-IR above 2.5
• Fasting glucose 100 to 110 mg/dL
• HbA1c drift of 0.2% or more from baseline

Switch compounds if:

• Lipid panel deteriorates significantly (rare, suggests interaction with concurrent AAS, not the peptides)
• Free T4 drops below the lower limit of normal with symptoms
• Cycle 3 of CJC/Ipa produces diminishing IGF-1 response (consider GHS-R downregulation, take a 6 to 8 week break)

Hold the line and recheck if:

• IGF-1 between 300 and 400 ng/mL, IGFBP-3 proportional, HOMA-IR below 2.0, HbA1c stable. This is the sweet spot.

Key takeaways

• CJC-1295 no-DAC plus ipamorelin produces one pulsatile GH release per injection, preserving insulin sensitivity between pulses. This is the core advantage over MK-677.
• IGF-1 is the efficacy marker. Pair with IGFBP-3 and watch the ratio, not just absolute IGF-1.
• Expect 15 to 40% IGF-1 rise at pre-bed single dosing. Higher dosing frequencies push higher, with diminishing returns.
• Ipamorelin does not raise cortisol or prolactin at therapeutic doses (Raun 1998). If yours does, your product is not real ipamorelin.
• Fasting glucose, HbA1c, HOMA-IR should barely move on CJC/Ipa. If they do, look at concurrent compounds, diet, or training stress before blaming the peptides.
• Tesamorelin has the strongest published evidence for the GHRH class. Worth considering for users over 40 with visceral fat or elevated triglycerides.
• Draw timing matters: fasted morning, 12 to 16 hours post-injection. Drawing too soon is the most common reason "flat" IGF-1 results show up.
• Stack with a GLP-1 only if you understand the lean mass tradeoff. CJC/Ipa is rational protection against deficit-driven muscle loss.
• Action thresholds: IGF-1 above 400 ng/mL means lower dose. Above 500 ng/mL or HOMA-IR above 2.5 means pause. Persistent cortisol or prolactin elevation means your product is suspect.

---

References

1. Bowers, C. Y., Reynolds, G. A., Durham, D., Barrera, C. M., Pezzoli, S. S., & Thorner, M. O. (1990). Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism, 70(4), 975-982. PubMed
2. Christ, E. R., Cummings, M. H., Jackson, N., et al. (2004). Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: A stable isotope study. Journal of Clinical Endocrinology and Metabolism, 89(4), 1801-1807. PubMed
3. Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology and Metabolism, 95(9), 4291-4304. PubMed
4. Arvat, E., di Vito, L., Maccagno, B., Broglio, F., Boghen, M. F., Deghenghi, R., Camanni, F., & Ghigo, E. (1997). Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides, 18(6), 885-891. PubMed
5. Losa, M., Scavini, M., Gatti, E., Rossini, A., Madaschi, S., Formenti, I., Caumo, A., Stidley, C. A., & Lanzi, R. (2008). Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid, 18(12), 1249-1254. PubMed
6. Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E. Jr., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: A randomized trial. Annals of Internal Medicine, 149(9), 601-611. PubMed
7. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PubMed
8. Sabbah, N., Wolf, P., Piedvache, C., Trabado, S., Verdelet, T., Cornu, C., Souberbielle, J. C., & Chanson, P. (2021). Reference values for IGF-I serum concentration in an adult population: Use of the VARIETE cohort for two new immunoassays. Endocrine Connections, 10(9), 1016-1026. PubMed
9. Sigalos, J. T., Pastuszak, A. W., Allison, A., Ohlander, S. J., Herati, A., Lindgren, M. C., & Lipshultz, L. I. (2017). Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. American Journal of Men's Health, 11(6), 1752-1757. PubMed
10. Siklar, Z., Ocal, G., Berberoğlu, M., & Bilir, P. (2009). Combined evaluation of IGF-1 and IGFBP-3 as an index of efficacy and safety in growth hormone treated patients. Journal of Clinical Research in Pediatric Endocrinology, 1(6), 274-280. PubMed
11. Smyczynska, J., Hilczer, M., Stawerska, R., & Lewinski, A. (2010). Thyroid function in children with growth hormone (GH) deficiency during the initial phase of GH replacement therapy: Clinical implications. Thyroid Research, 3, 2. PubMed
12. Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology and Metabolism, 96(1), 150-158. PubMed
13. Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805. PubMed
14. Tiulpakov, A. N., Brook, C. G., Pringle, P. J., Peterkova, V. A., Volevodz, N. N., & Bowers, C. Y. (1995). GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers. Clinical Endocrinology, 43(4), 421-426. PubMed
15. Veldhuis, J. D., & Bowers, C. Y. (2009). Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. American Journal of Physiology: Endocrinology and Metabolism, 296(6), E1361-E1370. PubMed